Trust Grants $4.3 Million for Anti-fibrotic Research in Crohn’s Disease

Trust Grants $4.3 Million for Anti-fibrotic Research in Crohn’s Disease
To foster the development of tools to test new anti-fibrotic treatments in Crohn’s patients, the Leona M. and Harry B. Helmsley Charitable Trust has awarded $4.3 million to three medical centers to establish the Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium. The award goes to the Mayo Clinic, Robarts Clinical Trials, and the Cleveland Clinic, which will coordinate the effort. Physicians co-leading the consortium are the Cleveland Clinic’s Florian Rieder, the Mayo Clinic’s Joel Fletcher, and Brian Feagan of Robarts Clinical Trials. The consortium plans to leverage each center’s know-how to create and test a patient-reported outcome tool that assesses the effects of Crohn’s disease, a common form of inflammatory bowel disease (IBD). Researchers also plan to develop an imaging system to measure the response of strictures to anti-fibrotic treatments. In IBD, and particularly Crohn’s, swelling and scar tissue formation often cause obstruction. This  results in bowel wall thickening and narrowed intestinal passage. Up to 40 percent of patients will ultimately develop the condition. Called fibrotic strictures, the narrowed areas can cause abdominal pain, vomiting, and bloating. There are no non-invasive wa
Subscribe or to access all post and page content.